Does EVO ICL have FDA approval? The FDA approved EVO ICL for the treatment of nearsightedness in 2005. The newest generation of EVO ICL was re-approved in 2022. What causes nearsightedness? Myopia most often occurs when the eyeball has an oval shape that is longer than average. In some...
从ICL V4到Toric ICL V4,再到EVO ICL,ICL在中国呈现迅猛发展的态势,而且ICL不仅矫正高度近视患者,在中低度近视患者中也有比较好的应用表现。 《2022中、欧国际近视手术白皮书》大数据报告中显示,2018-2021年ICL术式选择的人群占比逐年...
This is the largest US commercial use outcomes paper to-date following FDA approval of EVO/EVO+. Also of note is a new diagnostics comparison study by J. Morgan Micheletti, MD, ABO, FACS, which demonstrates...
today announced that the U.S. Food and Drug Administration (FDA) has granted approval of the EVO/EVO+ Visian® Implantable Collamer® Lens (“EVO”) for the correction of myopia and
The EVO ICL has gained popularity for the treatment of moderate myopia because it has demonstrated safety and effectiveness comparable to corneal laser refractive surgery.7 Based on clinical outcomes from US FDA premarket approval studies enrolling subjects with similar baseline refract...